Narrative review highlights microbiome-derived metabolite signaling in chronic inflammatory diseases, suggesting new routes for targeted therapeutics.
Chronic inflammation underlies autoimmune, metabolic, cardiovascular, and neurodegenerative disorders and remains difficult to manage because current anti-inflammatory therapies often have systemic adverse effects and variable clinical efficacy. This review synthesizes evidence on microbiome-associated metabolites relevant to inflammation, including short-chain fatty acids, microbial indole derivatives, secondary bile acids, polyamines, trimethylamine N-oxide, and selected host-microbe co-metabolites. These compounds regulate host immunity through G-protein-coupled receptors, nuclear receptors, epigenetic mechanisms, inflammasome regulation, and major inflammatory signaling pathways such as NF-kappaB, MAPK, and JAK-STAT. The translational potential of direct metabolite administration, prodrug design, microbiome engineering, dietary modulation, and targeted delivery systems is discussed alongside key limitations, including low bioavailability, context-dependent activity, interindividual microbiome variation, incomplete pharmacokinetic data, and the limited number of well-controlled human trials. Overall, microbiome-associated metabolites represent promising but still evolving therapeutic candidates; their clinical use requires stronger causal evidence, standardized formulations, safety evaluation, and disease-specific validation. Microbiome-associated metabolites, including short-chain fatty acids, microbial indole derivatives, secondary bile acids, and polyamines, contribute to epithelial homeostasis and regulate immune signaling through pathways such as NF-kappaB, MAPK, JAK-STAT, inflammasome activation, GPCR signaling, and epigenetic remodeling. Therapeutic strategies such as metabolite supplementation, prodrug design, microbiome engineering, and nano-delivery systems may enable targeted anti-inflammatory effects, but their clinical application remains dependent on stronger human evidence and standardized delivery approaches.
No takes yet. Share an insight, caveat, or question.
Sarma et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: